Inventor · disambiguated record
Mitchell E. Reff
Also filed as: RASTETTER WILLIAM H · REFF MITCHELL · REFF MITCHELL E · REFF MITCHELL ELLIOT
24 granted patents·14 pending applications·3,927 citations·filing 1993–2008
98Inventor score
Top patents by PatentIndex Score
38 records- 0199US7422739B2Anti-CD20 antibodiesBIOGEN IDEC INC·Filed 2001·Granted Sep 9, 2008·166 cites·13 claims
- 0299US5736137ATherapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMA CORP·Filed 1993·Granted Apr 7, 1998·1.6k cites·6 claims
- 0398US6399061B1Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphomaIDEC PHARMA CORP·Filed 1995·Granted Jun 4, 2002·254 cites·7 claims
- 0498US5843439ATherapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaFiled 1995·Granted Dec 1, 1998·336 cites·7 claims
- 0598US5776456ATherapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMA CORP·Filed 1995·Granted Jul 7, 1998·527 cites·14 claims
- 0697US6682734B1Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMA CORP·Filed 1995·Granted Jan 27, 2004·176 cites·13 claims
- 0797US6136310ARecombinant anti-CD4 antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted Oct 24, 2000·186 cites·16 claims
- 0896US7381560B2Expression and use of anti-CD20 antibodiesBIOGEN IDEC INC·Filed 2001·Granted Jun 3, 2008·45 cites·10 claims
- 0994US6159730AImpaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising sameIDEC PHARMA CORP·Filed 1999·Granted Dec 12, 2000·123 cites·27 claims
- 1093US7744877B2Expression and use of anti-CD20 AntibodiesBIOGEN IDEC INC·Filed 2002·Granted Jun 29, 2010·38 cites·8 claims
- 1193US7338658B2Recombinant anti-CD4 antibodies for human therapyBIOGEN IDEC INC·Filed 2002·Granted Mar 4, 2008·36 cites·7 claims
- 1291US5830698AMethod for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the sameIDEC PHARMA CORP·Filed 1997·Granted Nov 3, 1998·76 cites·38 claims
- 1390US6011138AGamma-1 anti-human CD23 monoclonal antibodiesIDEC PHARMA CORP·Filed 1997·Granted Jan 4, 2000·93 cites·20 claims
- 1490US5733779AImpaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising sameIDEC PHARMA CORP·Filed 1995·Granted Mar 31, 1998·85 cites·30 claims
- 1588US8603473B2Modified binding molecules comprising connecting peptidesGLASER SCOTT·Filed 2008·Granted Dec 10, 2013·14 cites·50 claims
- 1688US7033589B1γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeuticsBIOGEN IDEC INC·Filed 1999·Granted Apr 25, 2006·53 cites·15 claims
- 1785US5648267AImpaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising sameIDEC PHARMA CORP·Filed 1993·Granted Jul 15, 1997·82 cites·10 claims
- 1882US7438906B2Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeuticsBIOGEN IDEC INC·Filed 2005·Granted Oct 21, 2008·3 cites·24 claims
- 1981US7223392B2Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeuticsBIOGEN IDEC INC·Filed 2002·Granted May 29, 2007·10 cites·44 claims
- 2078US7452534B1Recombinant anti-CD4 antibodies for human therapyBIOGEN IDEC INC·Filed 2000·Granted Nov 18, 2008·7 cites·18 claims
- 2173US6017733AImpaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising sameIDEC PHARMA CORP·Filed 1998·Granted Jan 25, 2000·24 cites·10 claims
- 2271US7332163B2Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeuticsBIOGEN IDEC INC·Filed 2004·Granted Feb 19, 2008·3 cites·37 claims
- 2366US2009221036A1Recombinant anti-cd4 antibodies for human therapyBIOGEN IDEC INC·Filed 2008·Application pending·0 cites
- 2465US7695940B2Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeuticsBIOGEN IDEC INC·Filed 2007·Granted Apr 13, 2010·0 cites·45 claims
- 2565US6893636B2Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeuticsBIOGEN IDEC INC·Filed 1998·Granted May 17, 2005·13 cites·27 claims
- 2665US2009226430A1Recombinant anti-cd4 antibodies for human therapyBIOGEN IDEC INC·Filed 2008·Application pending·0 cites
- 2765US2005118175A1Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeuticsBIOGEN IDEC INC·Filed 2004·Application pending·0 cites
- 2861US2007065434A1Gamma-1 And Gamma-3 Anti-Human CD23 Monoclonal Antibodies And Use Thereof As TherapeuticsBIOGEN IDEC INC·Filed 2006·Application pending·0 cites
- 2961US2007065435A1Gamma-1 And Gamma-3 Anti-Human CD23 Monoclonal Antibodies And Use Thereof As TherapeuticsBIOGEN IDEC INC·Filed 2006·Application pending·0 cites
- 3060US2005186205A1Therapeutic application of chimeric and radiolabeled antibodies to human B Lymphocyte restricted differentiation antigen for treatment of B cell LymphomaFiled 2004·Application pending·0 cites
- 3160US2003021781A1Therapeutic application of chimeric and radiolabelled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMA CORP·Filed 2001·Application pending·0 cites
- 3253US2003036113A1Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising sameFiled 2001·Application pending·0 cites
- 3353US2006121028A1Variant IgG3 RITUXAN and therapeutic uses thereofBIOGEN IDEC INC·Filed 2006·Application pending·0 cites
- 3453US2002128448A1Variant IgG3 Rituxan and therapeutic use thereofIDEC PHARMA CORP·Filed 2001·Application pending·0 cites
- 3549US2013183288A1Non-fucosylated antibodiesREFF MITCHELL·Filed 2008·Application pending·0 cites
- 3649US2003157641A1Polycistronic expression of antibodiesIDEC PHARMA CORP·Filed 2002·Application pending·0 cites
- 3748US2003082172A1Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMACEUTICALS·Filed 2002·Application pending·0 cites
- 3837US2003003097A1Recombinant antibodies coexpressed with GnTIIIIDEC PHARMA CORP·Filed 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mitchell E. Reff files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →